# A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

> **NCT04022876** · PHASE1 · TERMINATED · sponsor: **Aileron Therapeutics, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Small-cell Lung Cancer

## Interventions

- **DRUG:** ALRN-6924
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Placebo
- **DRUG:** ALRN-6924
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT04022876
- **Lead sponsor:** Aileron Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-03
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** With a favorable safety profile the difference between treatment groups for the primary composite endpoint was not sufficient to generate statistically significant results with the targeted sample size
- **Last updated:** 2022-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04022876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04022876, "A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04022876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*